HNF1A Gene MODY Type 3 Genetic Test in UAE

Executive Summary & Core Metrics

Executive Summary: This single-gene next‑generation sequencing test confirms Maturity‑Onset Diabetes of the Young (MODY) type 3 by detecting pathogenic HNF1A variants. The analysis delivers 99.9% diagnostic sensitivity through ISO‑accredited processes and includes specialist interpretation for precise clinical guidance.

✓Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
✓Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Available daily 8 AM – 11 PM).
✓Clinical Guidance: Telephonic Post‑Test Clinical Guidance in Result Interpretation by DHA‑Licensed Specialists.
✓Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The HNF1A gene MODY Type 3 NGS test detects pathogenic variants causing maturity‑onset diabetes of the young, a monogenic form of diabetes that often mimics Type 1 or Type 2 diabetes but requires distinct management. This single‑gene analysis empowers clinicians to confirm a molecular diagnosis, guide sulfonylurea therapy, and screen at‑risk relatives with unmatched precision.

Feature	Our Test (Premium MODY3 NGS)	Closest Alternative (Generic Diabetes Panel)
Technology	Next‑Generation Sequencing (NGS) with full gene coverage & copy‑number analysis	PCR‑based targeted genotyping (limited to few SNPs)
Sensitivity	99.9% analytical sensitivity for single nucleotide variants & small indels	Variable; misses up to 30% of causal mutations
Turnaround Time	3–4 weeks with optional STAT reporting	4–6 weeks
Clinical Report	Interpreted by DHA‑licensed diabetologist & board‑certified geneticist	Automated bioinformatics report without specialist sign‑off

Physician Insight & Safety Protocols

“A positive HNF1A mutation result not only confirms MODY but also opens the door to sulfonylurea therapy, often replacing insulin. Yet, every result must be correlated with the full clinical picture; a negative result does not exclude other genetic or acquired forms of diabetes. Please discuss every report with your managing physician.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA ID: 9294403

⚠️ Medication Warning

Do not discontinue prescribed medication without consulting your doctor. This genetic test does not provide immediate treatment guidance. Any change in diabetes management must be supervised by your endocrinologist.

⚕️ Safety Exclusion Criteria & Emergency Red Flags

Exclusion: Subjects unable to give valid informed consent (unless authorized legal guardian provides consent under UAE Federal Decree‑Law No. 4 of 2016 on Medical Liability).
Exclusion: Acute metabolic decompensation (e.g., diabetic ketoacidosis) requiring immediate hospitalization; genetic testing can be done after stabilization.
ER Red Flag: If you experience severe hyperglycemia (blood glucose >250 mg/dL) with confusion, vomiting, or fruity breath odor, proceed to the nearest emergency department before test scheduling.
Pediatric testing of minors strictly adheres to UAE Federal Law No. 2 of 2019 concerning the Use of Information and Communication Technology in Health Fields with mandatory guardian presence and genetic counseling.

Patient FAQ & Clinical Guidance

1. What is the HNF1A MODY3 test, and how is it performed?

The test uses next‑generation sequencing to analyze all coding regions of the HNF1A gene from a blood sample or a single drop of blood on an FTA card. A painless venous blood draw (or finger‑prick for card) is collected by a DHA‑licensed phlebotomist during an at‑home visit, and the specimen is transported in a cold‑chain to our ISO 9001:2015 certified laboratory for sequencing and interpretation.

2. Who should consider this genetic test?

Individuals with diabetes diagnosed before age 25, a strong family history of diabetes across generations, absence of pancreatic autoantibodies, or those who respond unusually well to sulfonylureas should consider HNF1A MODY testing to differentiate monogenic from type 1/2 diabetes.

3. What do the results mean, and what happens after?

If the NGS identifies a pathogenic HNF1A variant, your endocrinologist can often transition therapy from insulin to sulfonylurea medications, improving glycemic control and quality of life. You will receive a comprehensive clinical report with DHA‑licensed specialist interpretation, followed by a telephonic counseling session to discuss the next steps in your care plan.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance: This service fully adheres to Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for data privacy, and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for health data security. Our laboratory holds ISO 9001:2015 Certification (Cert: INT/EGQ/2509DA/3139) and operates under DHA Facility License No. 1143.

Clinical & Logistical Metadata

Test Name	HNF1A Gene MODY Type 3 Genetic Test
Price (AED)	2,800 AED
Turnaround Time	3–4 weeks (optional STAT reporting)
Sample Type / Matrix	Whole blood (venous) or FTA card (finger‑prick)
Methodology Used	Next‑Generation Sequencing (NGS) – Full gene coverage & copy number analysis
ICD-10-CM Code	E13.9
LOINC Code	92807-7
DHA Facility License & Laboratory Address	DHA License: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE